More on Perrigo (PRGO -6%) FQ4: net profit +25% to $107.05M. Sales breakdown: Consumer Healthcare +12%, Nutritionals +10%, Rx Pharmaceuticals +70%. FY 2013 guidance: adjusted EPS $5.30-$5.50 vs. $4.99 in the previous year and consensus of $5.42. Apart from the revenue miss, it's hard to see why the shares are getting battered.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs